PALVELLA THERAPEUTICS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PALVELLA THERAPEUTICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $42.81M | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $25.90M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $31.42M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $29.32M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $46.28M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $29.10M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $25.28M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $5.83M | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $2.93M | Mar 30, 2017 |
| FY2015 | Dec 31, 2014 | $5.37M | Mar 23, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $43.65M | Mar 13, 2020 |
| FY2019 | Dec 31, 2018 | $27.25M | Mar 13, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($41.72M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($17.43M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $18.69M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($33.28M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($45.74M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($37.23M) | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | ($25.47M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($26.75M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($17.65M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($22.80M) | Mar 15, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($38.60M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($14.10M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($11.87M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($43.47M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($51.83M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($33.92M) | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | ($27.16M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($30.83M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($14.59M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($22.76M) | Mar 15, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.84M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $8.15M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $8.79M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $52.98M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $66.66M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $46.53M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $55.00M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $41.49M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $22.29M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $19.70M | Mar 15, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($25.01M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($10.84M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($13.70M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($59.93M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($7.66M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($45.90M) | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | ($52.47M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.07M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $49.75M | Mar 18, 2019 |
| FY2014 | Jun 30, 2014 | ($15.1K) | Sep 12, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $171.0K | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $1.04M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $949.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.73M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $2.46M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.70M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.95M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $560.0K | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $620.7K | Mar 30, 2017 |
| FY2015 | Dec 31, 2014 | $267.4K | Mar 23, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.56M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $88.23M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $7.55M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $95.49M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $153.56M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $105.01M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $141.10M | Mar 31, 2021 |
| FY2019 | Jan 1, 2019 | $143.18M | Mar 13, 2020 |
| FY2019 | Dec 31, 2018 | $141.34M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $103.88M | Mar 18, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.58M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $25.63M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $11.43M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $67.56M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $102.81M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $73.98M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $89.75M | Mar 31, 2021 |
| FY2019 | Jan 1, 2019 | $104.88M | Mar 13, 2020 |
| FY2019 | Dec 31, 2018 | $101.41M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $92.35M | Mar 18, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.98M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $62.61M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($74.48M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($93.78M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $50.76M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $31.03M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $51.35M | Mar 2, 2022 |
| FY2019 | Jan 1, 2019 | $38.29M | Mar 13, 2020 |
| FY2020 | Dec 31, 2018 | $39.94M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $11.52M | Mar 13, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($135.45M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($93.74M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($76.30M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($290.42M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($257.14M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($211.41M) | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | ($174.18M) | Mar 31, 2021 |
| FY2019 | Jan 1, 2019 | ($148.71M) | Mar 13, 2020 |
| FY2019 | Dec 31, 2018 | ($147.07M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($120.31M) | Mar 18, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.98M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $83.60M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $7.35M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $38.64M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $117.76M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $70.44M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $62.26M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $74.87M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $37.88M | Mar 18, 2019 |
| FY2018 | Dec 31, 2016 | $29.36M | Mar 18, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (7) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 2 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 2, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (7) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 2 | Mar 31, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 2, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 2, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 12.38M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 11.01M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 1.77M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 74.52M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 72.22M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 56.00M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | 55.21M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 54.15M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | 45.02M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 43.06M | Mar 15, 2018 |